Concert Pharmaceuticals Inc
NASDAQ:CNCE
Concert Pharmaceuticals Inc
Total Current Liabilities
Concert Pharmaceuticals Inc
Total Current Liabilities Peer Comparison
Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors
Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Concert Pharmaceuticals Inc
NASDAQ:CNCE
|
Total Current Liabilities
$16.1m
|
CAGR 3-Years
23%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$41.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
24%
|
CAGR 10-Years
21%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$13B
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$19.7B
|
CAGR 3-Years
15%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.8B
|
CAGR 3-Years
25%
|
CAGR 5-Years
28%
|
CAGR 10-Years
26%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Liabilities
$3.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
19%
|
CAGR 10-Years
28%
|
See Also
What is Concert Pharmaceuticals Inc's Total Current Liabilities?
Total Current Liabilities
16.1m
USD
Based on the financial report for Dec 31, 2021, Concert Pharmaceuticals Inc's Total Current Liabilities amounts to 16.1m USD.
What is Concert Pharmaceuticals Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
24%
Over the last year, the Total Current Liabilities growth was 58%. The average annual Total Current Liabilities growth rates for Concert Pharmaceuticals Inc have been 23% over the past three years , 24% over the past five years .